Postmarket Safety Events Among Novel Therapeutics Approved by the US Food and Drug Administration Between 2001 and 2010

Ventus and Genentech partner for small-molecule medicine discovery

Acquisition strengthens Aspire Pharma’s strategic portfolio

Alkermes has agreed to acquire Avadel Pharmaceuticals for up to $20 per share in cash, valuing Avadel at $2.1bn.

NanoViricides reports antiviral activity of NV-387 against measles in preclinical studies